Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: Wright Reports
Provider: New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biogen Idec Inc Completes Purchase Of Full Rights And Control Of TYSABRI

Tuesday, 2 Apr 2013 04:30pm EDT 

Biogen Idec Inc announced that it has completed its purchase of Elan Corporation's interest in TYSABRI (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI. The transaction was originally announced on February 6, 2013. 

Company Quote

0.52 +0.16%
22 Sep 2014